QST-Pupillometry in Sickle Cell Disease Patients

Completed

Conditions studied: SCD With Severe Phenotype (HbSS, HbSβ0 Thalassemia, HbSOARab)

In brief

There has been little progress for effective treatment of pain in sickle cell disease (SCD) patients. Many organizations have recognized that understanding the causes and reducing the burden of pain in SCD is critical in order to improve the quality of life in SCD patients. As patients with SCD face the challenge of living with both acute and chronic pain which is often improperly treated, our translational and interdisciplinary project aims to identify objective measures of pain sensitivity and its biochemical and genetic correlates. We hypothesize that SCD patients will have decreased tolerance to thermal and electrical stimuli.

Key facts

Study ID

NCT02242058

Run by

Julia Finkel

People needed

96

Starts

2013-08-01

Expected to finish

2018-11-01

Last updated by the study team

2020-01-21

Who can join

Age: 13 and older, up to 30. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• SCD with severe phenotype (HbSS, HbSbeta0 thalassemia, HbSOArab)
• Relatives of SCD patients who do not have sickle cell trait or SCD; healthy controls

You may not qualify if…

• Completed overt clinical stroke or transient ischemic attack;
• Known severe vasculopathy or Moyamoya disease on brain MRA (Magnetic Resonance Angiography).
• history of having consumed alcohol within the last 12 hours prior to testing.

Where it is running

• Children's National Health System — Washington D.C., District of Columbia, United States
• Children's National Medical Center — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.